Behzadi Ashkan Heshmatzadeh, Haghani Leila, D'Souza Donna L, Flanagan Siobhan, Jones Christopher
Division of Interventional Radiology, Department of Radiology, University of Minnesota, Minneapolis, Minnesota.
Department of Interventional Radiology, Memorial Sloan Kettering, New York City, New York.
Semin Intervent Radiol. 2024 Mar 14;41(1):48-55. doi: 10.1055/s-0044-1779714. eCollection 2024 Feb.
Transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) are common liver-directed therapies (LDTs) for unresectable HCC. While both deliver intra-arterial treatment directly to the site of the tumor, they differ in mechanisms of action and side effects. Several studies have compared their side effect profile, time to progression, and overall survival data, but often these lack practical considerations when choosing which treatment modality to use. Many factors can impact operator's choice for treatment, and the choice depends on treatment availability, cost, insurance coverage, operator's comfort level, patient-specific factors, tumor location, tumor biology, and disease stage. This review discusses survival data, time to progression data, as well as more practical patient and tumor characteristics for personalized LDT with TACE or TARE.
经动脉化疗栓塞术（TACE）和经动脉放射性栓塞术（TARE）是用于不可切除肝细胞癌（HCC）的常见肝脏定向治疗（LDT）。虽然两者都将动脉内治疗直接送达肿瘤部位，但它们在作用机制和副作用方面有所不同。多项研究比较了它们的副作用特征、疾病进展时间和总生存数据，但在选择使用哪种治疗方式时，这些研究往往缺乏实际考量。许多因素会影响操作者的治疗选择，而选择取决于治疗的可及性、成本、保险覆盖范围、操作者的熟练程度、患者特定因素、肿瘤位置、肿瘤生物学特性和疾病分期。本综述讨论了生存数据、疾病进展时间数据，以及用于TACE或TARE个性化LDT的更实际的患者和肿瘤特征。
